Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Realm Therapeutics plc

27 Nov 2018 18:28

RNS Number : 6877I
Realm Therapeutics PLC
27 November 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

RA Capital Management, LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Peter Kolchinsky (as the managing member of RA Capital Management, LLC)

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Realm Therapeutics plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

26 November 2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

7,181,699

6.16%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

7,181,699

6.16%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares

Sale - 2018 11 26

250,000

GBp 8.00

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

27 November 2018

Contact name:

Peter Kolchinsky

Telephone number*:

1-617-778-2500

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETUBRWRWRAAUAA
Date   Source Headline
5th Sep 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSRe Settlement with Misonix
15th Jun 201110:06 amRNSResult of AGM
18th May 20117:00 amRNSAnnual Information Update
17th May 20114:58 pmRNSUK Division Update
6th May 20117:00 amRNSAnnual Report and Accounts Available
28th Apr 20116:21 pmRNSFinal Results
28th Apr 20116:21 pmRNSInterim Management Statement
4th Apr 20112:29 pmRNSHolding(s) in Company
31st Mar 20114:53 pmRNSHolding(s) in Company
31st Mar 20114:52 pmRNSHolding(s) in Company
31st Mar 20114:51 pmRNSHolding(s) in Company
31st Mar 20117:00 amRNSTotal Voting Rights
22nd Mar 20117:00 amRNSPlacing of New Ordinary Shares
15th Mar 20114:24 pmRNSPotential Sale of Endoscopy Division
4th Feb 201111:51 amRNSBlocklisting Interim Review
2nd Feb 20111:18 pmRNSPre-Close Trading Update
9th Dec 20108:58 amRNSBlocklisting Interim Review
30th Nov 20107:00 amRNSChange of Adviser
8th Nov 20107:00 amRNSInterim Management Statement
29th Oct 20109:56 amRNSResult of General Meeting
11th Oct 20104:00 pmRNSProposed New Long Term Incentive Plan
2nd Sep 20102:44 pmRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHalf Yearly Report
9th Aug 20107:00 amRNSTrading Statement
22nd Jul 20101:36 pmRNSHolding(s) in Company
22nd Jul 20101:30 pmRNSHolding(s) in Company
30th Jun 20109:47 amRNSResult of AGM
21st Jun 20101:10 pmRNSReplacement: Director/PDMR Shareholding
21st Jun 20107:00 amRNSDirector/PDMR Shareholding
16th Jun 20107:00 amRNSBoard Change
14th Jun 20101:38 pmRNS2010 General Meeting Results
14th Jun 20109:16 amRNSAnnual Information Update
28th May 20102:55 pmRNSPublication of Circular
28th May 20107:32 amRNSResumption of Trading
28th May 20107:30 amRNSRestoration
28th May 20107:02 amRNSInterim Management Statement
28th May 20107:01 amRNSFinal Results
28th May 20107:00 amRNSIssue of Secured Convertible Loan Notes
24th May 20102:55 pmRNSHolding(s) in Company
30th Apr 20107:54 amRNSTemporary Suspension
30th Apr 20107:30 amRNSTemporary Suspension - PuriCore Plc
23rd Apr 20107:00 amRNSPuriCore Raises $1.8 Million
24th Feb 20107:00 amRNSBlocklisting Interim Review
20th Jan 20107:00 amRNSTrading Statement
4th Dec 20097:00 amRNSWins Emerging Life Sciences Company of the Year
12th Nov 20097:00 amRNSChange of Adviser
11th Nov 20092:00 pmRNSClinical Results for Vashe Wound Therapy
3rd Nov 20097:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.